Error in Figure: In the Original Investigation titled “Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy,”1 published online July 7, 2020, there was an error in Figure 2. In the scale in panel A, red should indicate 1.5 and blue should indicate 1.0. This article was corrected online.


Errors in Figures and Reference List: In the Original Investigation titled “Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis,”1 published online August 3, 2020, there were errors in Figures 2, 3, and 4. In Figure 2B, the heading for the middle graph should read “CD8+,” the first x-axis label should read “KLHL11+,” and the y-axis label should read “Increase in frequency of CD69 expressing CDB+ cells, %”; and the heading for the rightmost graph should read “CD4+,” the first x-axis label should read “KLHL11+,” and the y-axis label should read “Increase in frequency of CD69 expressing CDB+ cells, %.” In Figure 3F, there should be no arrowhead, and in Figure 3I, the label should read “CD3 staining showing KLHL11-IgG binding to cytoplasm of seminomatous cells.” In Figure 4A, both instances of “KLHL11-IgG seropositive” should read “testicular cancer detected,” and both instances of “KLHL11-IgG seronegative” should read “no testicular cancer detected.” In Figure 4B, the label should read “KLHL11-IgG vs Ma2 IgG seropositive,” the gray line should read “KLHL11-IgG seropositive,” the orange line should read “Ma2 IgG seropositive,” and the second line of “No. at risk” should read “Ma2 IgG seropositive.” This article was corrected online.


Errors in Figure: In the Original Investigation titled “Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTROLs): Bayesian Adaptive Comparative Effectiveness Randomized Trial,”1 published online August 17, 2020, there were errors in the figure. In the first column of boxes underneath “402 Patients randomized,” the first box should read “20 Randomized to receive nortriptyline at burn-in,” the second box should read “43 Enrolled at first interim,” the third box should read “43 Enrolled at second interim,” the fourth box should read “43 Enrolled at third interim,” the fifth box should read “43 Enrolled at fourth interim,” the sixth box should read “43 Enrolled at sixth interim,” the seventh box should read “43 Enrolled at sixth interim,” the eighth box should be removed, and the last box should read “43 Enrolled at sixth interim,” with all the numbers indented underneath that line. These changes to the wording in the boxes in the first column should also be made to the second, third, and fourth column while retaining their respective numbers and drug names. This article has been corrected online.